Combined Placental Maternal Floor Infarction and Cytomegalovirus Placentitis: A Case Report

Combined Placental Maternal Floor Infarction and Cytomegalovirus Placentitis: A Case Report

Mother’s infarction (MFI) and Masif Fibrin Perive (MPFD) deposition (MPFD) are unusual, related to the condition of the secondary placenta of trophoblastic cell damage. The etiology is unknown but MPFD / MFI is associated with adverse obstetric results and a significant risk of repeatment. Case Report: We report the MPFD / MFI case related to placentitis Cytomegalovirus (CMV). A 27-year-old mother gave birth to a man’s fetus born with a postmortem diagnosis of default CMV.

The placenta shows limfohistiocial villitis with isolated CMV inclusion, in combination with MFI. Villitis has an intermediary feature between unclean cmv placentitis and ethiological villitis (Vue). Conclusion: Vue is considered a reaction of an anti-fetal immune mother who resembles the refusal of allograft. We postulate that viral infections in our case may have triggered this immune response, considering that CMV antigens are known to be crossing with some human antigens, especially HLA. The next trophoblastic cell damage can then lead to MFI / MFPD.

Hemolytic uremic syndrome and atypical nephrotic syndrome associated with cytomegalovirus infection

Atypical hemolytic uremic syndrome (ahus) is a rare disease. It is produced from the disregulation of alternative complementary pathways on the cell surface which causes endothelial damage. Increasing evidence evidence, this disorder is for mutations in the complementary regulator gene or with autoantibodies to complementary factors. This mutation has incomplete penetration and variable phenotypes.

Cytomegalovirus (CMV) is endemic throughout the world, and the incidence of severe CMV disease in immunocompetent adults seems to be greater than previously thought. Ahus and nephrotic syndrome associated with CMV infection rarely occur. The identification of triggers for the manifestation of the ahus in patients who are vulnerable genetics is very important because this allows faster clinical treatment and improvement initiations. We reported a case of a man with the removal of homozygous CFHR3-1 whose initial presentation was ahus and nephrotic syndrome associated with CMV infection.

IgA binds epitop glycoprotein B and neutralizes human cytomegalovirus

Human Cytomegalovirus (HCMV) is a pathogen everywhere that has the potential for pathogens in immunosuppression individuals and pregnant women during primary infections. HCMV Envelope Glycoprotein B (GB) facilitates virus entries into all types of cells and induces strong immune responses. Epitope AD-2 is a very preserved GB Linear GB epitope and the critical target for antibodies, only 50% of seropositive individuals that make IgG antibodies to this site and the rib response has not been fully investigated.

This study aims to compare IGG and IGA responses to GB and Epitop AD-2 in individuals who are exposed to naturally and those who receive the recombinant Ajuvant GB / MF59 vaccine. Thus, seropositive individual vaccination increases the existing IGA and GB IGG levels and induces the rib response and specific IGG de Novo GB on seronegative receivers. The existing IgG response and AD-2 ribs were driven by vaccination but the response of De Novo AD-2 was not detected. Individuals exposed naturally have the dominant IgG response to GB and AD-2 compared to weaker rib responses and variables, although significant rib response to AD-2 was observed in the ASI ASI sample.

All antibodies tie the AD-2 contain a light chain of kappa while the use of a balanced capa / lambda light chain is found for those who bind to GB. The V-region matches the specific recombinant IGG AD-2 and ribs are bound to GB and AD-2 and neutralize HCMV infection in vitro. Overall, this result shows that even though the human IGG response dominates, class IGA antibodies against AD-2 are significant components of breast milk that can function to protect neonates from HCMV.

Cytomegalovirus After a kidney transplant in 2020: moving towards personalized prevention

Cytomegalovirus (CMV) – Close complications after kidney transplants remain a substantial challenge. Instead of applying a preventive strategy to all risky patients, we can now adjust our strategies at the individual patient level. The prophylaxis of antivirus or strict pre-emptive strategies may be optimal for patients with the highest risk for CMV, while lower risk patients can be profitable especially from pre-emptive monitoring and therapeutic administration only if needed.

CMV Special T-Testing may be useful to improve the determination of CMV risk in pre-transplants, and to guide decisions about the need for antivirus therapy or duration. Immunosupressive regimens including the target of the Rapamycin mammal inhibitor reduces the risk of CMV and thus can be an interesting choice in some patients. The new antivirus agent further expanded our therapy arsenal in the near future, and the prospect of CMV vaccination and remove cell therapy seems to be on the horizon.

Combined Placental Maternal Floor Infarction and Cytomegalovirus Placentitis: A Case Report

Cytomegalovirus Pre-Transplant Immunity and Risk of Viral Reactivation After Lung Transplantation: Prospective Cohort Study

Cytomegalovirus (CMV) remains a significant burden on the recipient of the lung transplant. Disadvantages in the immunity of the TP-transplant increases the risk of complications related to CMV. However, it is not clear if the underlying pre-transplant immunity increases risk. To assess this, we recruit 39 lung transplant patients and do quantiferon-CMV in their peripheral blood. More than a third of prospective cmv-seropositive transplant receivers are non-imun-reactive CMV (CMV-NIR) pre-transplant.

Hba Antibody

1-CSB-PA010147LA01MO
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against Hba. Recognizes Hba from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:1000-1:5000

HBA Polyclonal Antibody

ES11261-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against HBA from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

HBA Polyclonal Antibody

ES11261-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against HBA from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

HBA Polyclonal Antibody

ABP58750-003ml 0.03ml
EUR 158
  • Immunogen information: Synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110
  • Applications tips:
Description: A polyclonal antibody for detection of HBA from Human, Mouse, Rat. This HBA antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110

HBA Polyclonal Antibody

ABP58750-01ml 0.1ml
EUR 289
  • Immunogen information: Synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110
  • Applications tips:
Description: A polyclonal antibody for detection of HBA from Human, Mouse, Rat. This HBA antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110

HBA Polyclonal Antibody

ABP58750-02ml 0.2ml
EUR 414
  • Immunogen information: Synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110
  • Applications tips:
Description: A polyclonal antibody for detection of HBA from Human, Mouse, Rat. This HBA antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human HBA protein at amino acid sequence of 30-110

Hba Polyclonal Antibody

A53679 100 µg
EUR 570.55
Description: The best epigenetics products

Anti-HBA antibody

STJ192419 200 µl
EUR 197
Description: Unconjugated Rabbit polyclonal to HBA

Human Brain Astrocytes (HBA)

HMP202 500,000+ cells - Frozen
EUR 1080

Hba Antibody, HRP conjugated

1-CSB-PA010147LB01MO
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is HRP conjugated. Tested in the following application: ELISA

Hba Antibody, FITC conjugated

1-CSB-PA010147LC01MO
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is FITC conjugated. Tested in the following application: ELISA

Hba Antibody, Biotin conjugated

1-CSB-PA010147LD01MO
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is Biotin conjugated. Tested in the following application: ELISA

Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3266403 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3179403 1.0 ug DNA
EUR 154

Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3332403 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6915803 1.0 ug DNA
EUR 154

Hemoglobin Subunit Alpha (Hba) Antibody

20-abx109857
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Hba Polyclonal Antibody, HRP Conjugated

A53680 100 µg
EUR 570.55
Description: kits suitable for this type of research

Hba Polyclonal Antibody, FITC Conjugated

A53681 100 µg
EUR 570.55
Description: fast delivery possible

Hba Polyclonal Antibody, Biotin Conjugated

A53682 100 µg
EUR 570.55
Description: reagents widely cited

Mouse Hemoglobin subunit alpha (Hba)

1-CSB-YP010147MO
  • EUR 504.00
  • EUR 265.00
  • EUR 1832.00
  • EUR 763.00
  • EUR 1216.00
  • EUR 334.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 17 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Mouse Hemoglobin subunit alpha(Hba) expressed in Yeast

Mouse Hemoglobin subunit alpha (Hba)

1-CSB-EP010147MO
  • EUR 505.00
  • EUR 265.00
  • EUR 1827.00
  • EUR 766.00
  • EUR 1218.00
  • EUR 335.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 19 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Mouse Hemoglobin subunit alpha(Hba) expressed in E.coli

Hba-a2 Recombinant Protein (Rat)

RP204248 100 ug Ask for price

Hba-a1 Recombinant Protein (Mouse)

RP140990 100 ug Ask for price

Hba-a2 Recombinant Protein (Mouse)

RP140993 100 ug Ask for price

Hba-x Recombinant Protein (Mouse)

RP140996 100 ug Ask for price

HBA ELISA Kit (Bovine) (OKEH03848)

OKEH03848 96 Wells
EUR 779
Description: Description of target: Involved in oxygen transport from the lung to the various peripheral tissues.;Species reactivity: Bovine;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.59 ng/mL

HBA ELISA Kit (Mouse) (OKEH05810)

OKEH05810 96 Wells
EUR 662
Description: Description of target: Involved in oxygen transport from the lung to the various peripheral tissues. ;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.84 ng/mL

Rat Hemoglobin subunit alpha-1/2, HBA ELISA Kit

ELA-E0517r 96 Tests
EUR 886

Hba-a2 ORF Vector (Rat) (pORF)

ORF068084 1.0 ug DNA
EUR 506

Hba-a1 ORF Vector (Mouse) (pORF)

ORF046998 1.0 ug DNA
EUR 506

Hba-a2 ORF Vector (Mouse) (pORF)

ORF046999 1.0 ug DNA
EUR 506

Hba-x ORF Vector (Mouse) (pORF)

ORF047000 1.0 ug DNA
EUR 506

Human Anti-Influenza B virus IgA ELISA kit, 96 tests, Quantitative

920-410-HBA 1 Kit
EUR 712

Bovine HBA/ Hemoglobin subunit alpha ELISA Kit

E0304Bo 1 Kit
EUR 717

Human Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E05171h 96 Tests
EUR 824

Bovine Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E0517b 96 Tests
EUR 928

Chicken Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E0517c 96 Tests
EUR 928

Canine Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E0517d 96 Tests
EUR 928

Mouse Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E0517m 96 Tests
EUR 865

Porcine Hemoglobin subunit alpha, HBA ELISA Kit

ELA-E0517p 96 Tests
EUR 928

Hba-x sgRNA CRISPR Lentivector set (Mouse)

K3266401 3 x 1.0 ug
EUR 339

Hba-a2 sgRNA CRISPR Lentivector set (Mouse)

K3179401 3 x 1.0 ug
EUR 339

Hba-a1 sgRNA CRISPR Lentivector set (Mouse)

K3332401 3 x 1.0 ug
EUR 339

Hba-a2 sgRNA CRISPR Lentivector set (Rat)

K6915801 3 x 1.0 ug
EUR 339

2-Propyl-β-D-glucuronide, 2 mg

0904-2 2 mg
EUR 162

Hba-x sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3266407 1.0 ug DNA
EUR 167

Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3179407 1.0 ug DNA
EUR 167

Hba-a1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3332407 1.0 ug DNA
EUR 167

Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6915807 1.0 ug DNA
EUR 167

IL-2 Interleukin-2 Human Recombinant Protein, His Tag

PROTP60568-2 Regular: 10ug
EUR 317
Description: Interleukin-2 Human Recombinant produced in E.Coli is a single, non-glycosylated, Polypeptide chain containing 133 amino acids fragment (21-153) having a molecular weight of 20kDa and fused with a 4.5kDa amino-terminal hexahistidine tag. _x000D_ The IL-2 His is purified by proprietary chromatographic techniques._x000D_

BMP-2 Bone Morphogenetic Protein-2 Human Recombinant Protein, Monomer

PROTP12643-2 Regular: 20ug
EUR 317
Description: Bone Morphogenetic Protein-2 Human Recombinant produced in E.Coli is a monomeric, non-glycosylated, Polypeptide chain containing 115 amino acids (283-396) and having a molecular mass of 13009 Dalton. ;The BMP-2 is purified by proprietary chromatographic techniques.

Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3266402 1.0 ug DNA
EUR 154

Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3266404 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3179402 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3179404 1.0 ug DNA
EUR 154

Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3332402 1.0 ug DNA
EUR 154

Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3332404 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6915802 1.0 ug DNA
EUR 154

Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6915804 1.0 ug DNA
EUR 154

Hba-a2 Protein Vector (Rat) (pPB-C-His)

PV272334 500 ng
EUR 603

Hba-a2 Protein Vector (Rat) (pPB-N-His)

PV272335 500 ng
EUR 603

Hba-a2 Protein Vector (Rat) (pPM-C-HA)

PV272336 500 ng
EUR 603

Hba-a2 Protein Vector (Rat) (pPM-C-His)

PV272337 500 ng
EUR 603

Hba-a1 Protein Vector (Mouse) (pPB-C-His)

PV187990 500 ng
EUR 603

Hba-a1 Protein Vector (Mouse) (pPB-N-His)

PV187991 500 ng
EUR 603

Hba-a1 Protein Vector (Mouse) (pPM-C-HA)

PV187992 500 ng
EUR 603

Hba-a1 Protein Vector (Mouse) (pPM-C-His)

PV187993 500 ng
EUR 603

Hba-a2 Protein Vector (Mouse) (pPB-C-His)

PV187994 500 ng
EUR 603

Hba-a2 Protein Vector (Mouse) (pPB-N-His)

PV187995 500 ng
EUR 603

Hba-a2 Protein Vector (Mouse) (pPM-C-HA)

PV187996 500 ng
EUR 603

Hba-a2 Protein Vector (Mouse) (pPM-C-His)

PV187997 500 ng
EUR 603

Hba-x Protein Vector (Mouse) (pPB-C-His)

PV187998 500 ng
EUR 603

Hba-x Protein Vector (Mouse) (pPB-N-His)

PV187999 500 ng
EUR 603

Hba-x Protein Vector (Mouse) (pPM-C-HA)

PV188000 500 ng
EUR 603

Hba-x Protein Vector (Mouse) (pPM-C-His)

PV188001 500 ng
EUR 603

Hba-a2 3'UTR Luciferase Stable Cell Line

TU205653 1.0 ml Ask for price

Hba-a1 3'UTR GFP Stable Cell Line

TU159375 1.0 ml Ask for price

Hba-a2 3'UTR GFP Stable Cell Line

TU159376 1.0 ml Ask for price

Hba-x 3'UTR GFP Stable Cell Line

TU159377 1.0 ml Ask for price

Hba-a1 3'UTR Luciferase Stable Cell Line

TU109375 1.0 ml Ask for price

Hba-a2 3'UTR Luciferase Stable Cell Line

TU109376 1.0 ml Ask for price

Hba-x 3'UTR Luciferase Stable Cell Line

TU109377 1.0 ml Ask for price

Hba-a2 3'UTR GFP Stable Cell Line

TU255653 1.0 ml Ask for price

Individual Reaction Mix 2

G065-2 200 reactions
EUR 167

Anti-ErbB 2/ERBB2 Antibody

A00010-2 100ug/vial
EUR 334

Anti-Bcl-2/BCL2 Antibody

A00040-2 100ug/vial
EUR 334

Anti-Angiopoietin-2/ANGPT2 Antibody

A00370-2 100ug/vial
EUR 334

Anti-EIF4A1/2/3 Antibody

A03922-2 100ug/vial
EUR 334

Anti-Fascin 2/FSCN2 Antibody

A07840-2 100ug/vial
EUR 294

Dr. P Kit-Solution 2

K2021010-2 6 ml
EUR 120
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Recombinant Human BD-2 Protein

PROTO15263-2 20ug
EUR 317
Description: Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The α-defensins are distinguished from the β-defensins by the pairing of their three disulfide bonds. To date, six human β-defensins have been identified; BD-1, BD-2, BD-3, BD-4, BD-5 and BD-6. β-defensins are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, they can act as chemoattractants towards immature dendritic cells and memory T cells. The β-defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence and in some cases, a propeptide sequence. β-defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds. Recombinant human BD-2 is a 4.3 kDa protein containing 41 amino acid residues.

Recombinant Human Relaxin-2 Protein

PROTP04090-2 25ug
EUR 317
Description: Relaxin-2 is a peptide hormone structurally related to insulin, which is expressed in the placenta, decidua, prostate, and in the ovary during pregnancy. Of the three known relaxin genes, Relaxin-2 is the only relaxin known to circulate in the blood. Relaxin-2 binds specifically to the LGR7 and LGR8 receptors, previously identified as an “orphan” G protein coupled receptors. Signaling by Relaxin-2 through its target receptors enhances the growth of pubic ligaments and ripening of the cervix during birth. Recombinant Relaxin-2 is a nonglycosylated 6.0 kDa disulfide linked heterodimeric protein consisting of a 24 amino acid A-chain and a 29 amino acid B-chain.

Recombinant Murine IL-2 Protein

PROTP04351-2 20ug
EUR 317
Description: IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant murine IL-2 is a 17.2 kDa protein, containing 149 amino acid residues.

Recombinant Human PAI-2 Protein

PROTP05120-2 10ug
EUR 317
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.

Recombinant Human MMP-2 Protein

PROTP08253-2 10ug
EUR 317
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-2 is a secreted collagenase with specificity toward Type IV, V, VII, and X collagens. Recombinant human MMP-2 is a 62.0 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (552 amino acids).

pLenti-CARM1 shRNA-2 Plasmid

PVTBAV03691-2 2 ug
EUR 356

pLenti-CTLA4 shRNA-2 Plasmid

PVTBAV05689-2 2 ug
EUR 356

pLenti-FOXM1 shRNA-2 Plasmid

PVTBAV08732-2 2 ug
EUR 356

pLenti-JUN shRNA-2 Plasmid

PVTBAV11741-2 2 ug
EUR 356

pLenti-LHX6 shRNA-2 Plasmid

PVTBAV12881-2 2 ug
EUR 356

pLenti-MAGEA3 shRNA-2 Plasmid

PVTBAV13661-2 2 ug
EUR 356

pLenti-RUNX3 shRNA-2 Plasmid

PVTBAV20583-2 2 ug
EUR 356

pLenti-Slc7a11 shRNA-2 Plasmid

PVTBAV21973-2 2 ug
EUR 356

pLenti-STAT3 shRNA-2 Plasmid

PVTBAV22921-2 2 ug
EUR 356

pLenti-XRCC5 shRNA-2 Plasmid

PVTBAV26238-2 2 ug
EUR 356

Mouse FGF-2 Recombinant Protein

R00121-2 5ug/vial
EUR 259
Description: FGF basic (FGF2) is a multipotential fibroblast growth factor that stimulates and supports proliferation, migration and differentiation. Mouse FGF basic (FGF-2) Recombinant Protein is purified FGF basic (FGF-2) produced in yeast.

Chicken IL-2 Recombinant Protein

R00387-2 5ug/vial
EUR 259
Description: Interleukin-2 (IL-2) is a cytokine produced by T-helper cells in response to antigenic or mitogenic stimulation. It is required for T-cell proliferation and other activities crucial to the regulation of the immune response. Chicken IL-2 Recombinant Protein is purified interleukin-2 produced in yeast.

Recombinant Human TFF-2 Protein

PROTQ03403-2 20ug
EUR 317
Description: The Trefoil Factor peptides (TFF1, TFF2 and TFF3) are expressed in the gastrointestinal tract, and appear to play an important role in intestinal mucosal defense and repair. TFF2 has been shown to inhibit gastrointestinal motility and gastric acid secretion. Recent data suggests a potential role for TFF2 in acute and chronic asthma (Nikolaidis, N.M. et al. Am. Journal Respir. Cell Mol. Biol. (2003) 4: 458-464). Recombinant human TFF2 is a 12.0 kDa polypeptide of 107 amino acid residues, which includes a 40-amino acid trefoil motif containing three conserved intramolecular disulfide bonds.

Anti-COX2/Cyclooxygenase 2/PTGS2 Antibody

A00084-2 100ug/vial
EUR 294

Anti-beta 2 Microglobulin/B2m Antibody

A00456-2 100ug/vial
EUR 294

The CMV-NIR status is associated with the incidence of CMV reactivation transplantation which is significantly higher, indicating that the immunity of CMV dysfunctional in prospective lung transplant recipients is associated with an increased risk of viral viral-transplant reactivation.
Keywords: cytomegalovirus; T-cell immunity; solid organ transplant; Virus reactivation.

Leave A Comment